Additional Considerations Required While Assessing Betta Pharmaceuticals' (SZSE:300558) Strong Earnings
Additional Considerations Required While Assessing Betta Pharmaceuticals' (SZSE:300558) Strong Earnings
Betta Pharmaceuticals Co., Ltd. (SZSE:300558) announced strong profits, but the stock was stagnant. Our analysis suggests that this might be because shareholders have noticed some concerning underlying factors.
貝達藥業股份有限公司(SZSE:300558)宣佈營利強勁,但股票仍無動於衷。我們的分析表明,可能是股東已經注意到了一些令人擔憂的潛在因素。
How Do Unusual Items Influence Profit?
非常規項目如何影響利潤?
Importantly, our data indicates that Betta Pharmaceuticals' profit received a boost of CN¥93m in unusual items, over the last year. We can't deny that higher profits generally leave us optimistic, but we'd prefer it if the profit were to be sustainable. We ran the numbers on most publicly listed companies worldwide, and it's very common for unusual items to be once-off in nature. Which is hardly surprising, given the name. If Betta Pharmaceuticals doesn't see that contribution repeat, then all else being equal we'd expect its profit to drop over the current year.
重要的是,我們的數據表明,貝達藥業非常規項目的利潤在過去一年中獲得了9300萬元的提振。我們不得不承認,更高的利潤通常讓我們感到樂觀,但我們更希望利潤能夠持續增長。我們對全球大多數上市公司的數據進行了分析,發現非常規項目往往一次性出現。這並不令人驚訝,因爲這就是它的名稱所表達的。如果貝達藥業看不到這種貢獻的重現,那麼其他條件不變,我們預計其利潤將在當前年度下降。
That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.
這可能會讓您想知道分析師對未來盈利能力的預測。幸運的是,您可以單擊此處查看基於其估計的未來盈利能力的互動圖表。
Our Take On Betta Pharmaceuticals' Profit Performance
我們對貝達藥業的利潤表現的看法是
We'd posit that Betta Pharmaceuticals' statutory earnings aren't a clean read on ongoing productivity, due to the large unusual item. Therefore, it seems possible to us that Betta Pharmaceuticals' true underlying earnings power is actually less than its statutory profit. But the happy news is that, while acknowledging we have to look beyond the statutory numbers, those numbers are still improving, with EPS growing at a very high rate over the last year. The goal of this article has been to assess how well we can rely on the statutory earnings to reflect the company's potential, but there is plenty more to consider. In light of this, if you'd like to do more analysis on the company, it's vital to be informed of the risks involved. In terms of investment risks, we've identified 1 warning sign with Betta Pharmaceuticals, and understanding it should be part of your investment process.
我們認爲貝達藥業的法定收益並不是對持續生產力的清晰表達,因爲非常規項目佔比較大。因此,我們認爲貝達藥業的真正基礎收益能力實際上不如其法定利潤。但好消息是,在確認我們必須超越法定數字的前提下,這些數字仍在不斷提高,每股收益在過去一年內增長得非常快。這篇文章的目標是評估我們在多大程度上可以依賴法定收益來反映公司的潛力,但還有許多需要考慮的因素。考慮到這一點,如果您想要對公司進行更多的分析,了解投資過程中的風險是至關重要的。
Today we've zoomed in on a single data point to better understand the nature of Betta Pharmaceuticals' profit. But there is always more to discover if you are capable of focussing your mind on minutiae. Some people consider a high return on equity to be a good sign of a quality business. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks with significant insider holdings to be useful.
今天,我們聚焦貝達藥業的一個數據點,以更好地了解其利潤性質。但是,如果您能把注意力集中在細節上,就一定會發現更多。有些人認爲高回報率是優質企業的好跡象。雖然可能需要您自己進行一些研究,但您可能會發現這個免費的高回報率企業集合或這個擁有重要內部持股的股票列表很有用。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。